BackAllergy Therapeutics plc Overview
Allergy Therapeutics plc

Allergy Therapeutics plc Return on Equity

Valuation check: AGY.L's ROE is 891.64%, above the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

891.64%

Return on Equity

891.64%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Allergy Therapeutics plc (AGY.L) FAQ

The latest ROE for AGY.L is 891.64%. That is above the sector sector average of 11.3%. Investors often review this figure alongside Allergy Therapeutics plc's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, AGY.L currently prints 891.64% for ROE, while the sector average sits near 11.3%. That is roughly 7793.3% above the sector mean. Large gaps often invite a closer look at Allergy Therapeutics plc's growth, margins, and balance sheet.

Return on Equity shows how effectively Allergy Therapeutics plc converts resources into returns. At 891.64%, AGY.L may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AGY.L's ROE (891.64%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers